Last reviewed · How we verify

Propofol+ Rocuronium+ Fentanyl + Inhalational — Competitive Intelligence Brief

Propofol+ Rocuronium+ Fentanyl + Inhalational (Propofol+ Rocuronium+ Fentanyl + Inhalational) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: General anesthetic combination. Area: Anesthesiology.

phase 3 General anesthetic combination Anesthesiology Small molecule Live · refreshed every 30 min

Target snapshot

Propofol+ Rocuronium+ Fentanyl + Inhalational (Propofol+ Rocuronium+ Fentanyl + Inhalational) — Memorial Sloan Kettering Cancer Center. This is a combination anesthetic regimen that induces unconsciousness, provides muscle paralysis, and delivers pain relief for surgical procedures.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Propofol+ Rocuronium+ Fentanyl + Inhalational TARGET Propofol+ Rocuronium+ Fentanyl + Inhalational Memorial Sloan Kettering Cancer Center phase 3 General anesthetic combination
Remifentanil, Propofol, and Desflurane Remifentanil, Propofol, and Desflurane The Cooper Health System marketed General anesthetic combination Mu-opioid receptor (remifentanil); GABA-A receptor (propofol); multiple ion channels and neurotransmitter receptors (desflurane)
propofol，remifentanil，cis atracurium propofol，remifentanil，cis atracurium Tang-Du Hospital marketed General anesthetic combination (GABA agonist + opioid + neuromuscular blocker) GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)
Sevoflurane+Propofol Sevoflurane+Propofol Huazhong University of Science and Technology marketed General anesthetic combination GABA-A receptor
Remifentanil, propofol and citanest Remifentanil, propofol and citanest University of Aarhus marketed General anesthetic combination Mu opioid receptor (remifentanil); GABA-A receptor (propofol); Voltage-gated sodium channels (prilocaine)
Remifentanil, Dexmedetomidine, and Desflurane Remifentanil, Dexmedetomidine, and Desflurane The Cooper Health System marketed General anesthetic combination Mu-opioid receptor (remifentanil), alpha-2 adrenergic receptor (dexmedetomidine), GABA and other CNS targets (desflurane)
Anesthesia maintenance , propofol,remifentanil,cisatracurium Anesthesia maintenance , propofol,remifentanil,cisatracurium Second Affiliated Hospital of Xi'an Jiaotong University marketed General anesthetic combination (GABA-A agonist + opioid + neuromuscular blocker) GABA-A receptor (propofol); mu-opioid receptor (remifentanil); nicotinic acetylcholine receptor at neuromuscular junction (cisatracurium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (General anesthetic combination class)

  1. The Cooper Health System · 2 drugs in this class
  2. Fayoum University Hospital · 1 drug in this class
  3. Huazhong University of Science and Technology · 1 drug in this class
  4. Memorial Sloan Kettering Cancer Center · 1 drug in this class
  5. The Cleveland Clinic · 1 drug in this class
  6. University of Aarhus · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Propofol+ Rocuronium+ Fentanyl + Inhalational — Competitive Intelligence Brief. https://druglandscape.com/ci/propofol-rocuronium-fentanyl-inhalational. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: